Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

EDSA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Edesa Biotech, Inc.NASDAQ: EDSA

Depreciation & Amortization · Q2 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $25.87K rose 5.6% year over year, ahead of the -26.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 40.0% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +5.6% holds above the trailing-twelve-month pace of -26.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.87K-40.0% QoQ
Last fiscal yearSep 2025
$119.27K-35.9% YoY
LTMMar 2026
$120.64K-26.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.6%——
1 year-35.9%——
3-year CAGR+0.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
119.27K USD
Year-over-year change
-35.9%
4-year CAGR
+0.1%

Depreciation & Amortization vs competitors

How EDSA compares with its peers on the latest reported figures

  • EDSA's LTM Mar 2026 depreciation & amortization of $120.64K is the largest of the 2 companies compared; the peer median is $1.88K.
  • Its year-over-year change of -26.1% is the highest of 2, against a peer median of -89.0%.
EDSA Competitors Peer median
Depreciation & Amortization for EDSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EDSAEdesa Biotech, Inc.LTM Mar 2026$120.64K -26.1%+0.3%—
DWTXDogwood Therapeutics, Inc.LTM Mar 2026$1.88K -89.0%——
Peer median (excluding EDSA) $1.88K-89.0%——

Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(13.34M)(17.55M)(8.37M)(6.17M)(7.19M)
Depreciation & Amortization118.79K118.19K183.47K186.05K119.27K
Deferred Income Tax(3.31M)(2.38M)(308K)00
Stock-Based Compensation3.2M2.26M1.25M537.49K729.64K
Change in Working Capital(3.64M)2.89M308K571.07K(985.65K)
Accounts Receivables(3.23M)2.03B562.77K356.34K(377.99K)
Inventory00000
Accounts Payables(124.72K)882.84K(556.27K)00
Other Working Capital(281.36K)(2.03B)301.5K214.73K(607.67K)
Other Non-Cash Items3.31M2.38M308K(14.77K)0
Operating Cash Flow(13.66M)(12.28M)(6.64M)(4.89M)(7.32M)
Capital Expenditures(6.15K)(5.66K)300
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(3)00
Investing Cash Flow(6.15K)(5.66K)000
Debt Repayment000(29.53K)0
Common Stock Issued14.17M11.63M4.83M621.56K17.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow14.17M11.63M4.83M592.03K17.03M
Effect of Forex Changes121.9K(93.01K)76.85K(25.9K)46.22K
Net Change in Cash625.56K(748.34K)(1.73M)(4.32M)9.75M
Free Cash Flow(13.67M)(12.28M)(6.64M)(4.89M)(7.32M)

Edesa Biotech, Inc.

NASDAQ:EDSA

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.